Low ligand concentrations: Gαs-mediated cAMP/PKA pathway dominates, promoting metabolic and anti-inflammatory effects .
High ligand concentrations: Recruitment of Gαi and β-Arrestin leads to receptor desensitization and alternative pathways like MAPK/ERK .
Antisauvagine-30: Selective antagonist used to block CRHR2 in preclinical models .
2,2′:5′,2′′:5′′,2′′′-Quaterthiophene: Small-molecule antagonist under investigation for heart failure .
Acute UCN2 treatment in mice induces insulin resistance via CRHR2-Gαs signaling, while chronic exposure desensitizes the receptor, restoring glucose tolerance .
Phosphoproteomic analyses reveal UCN2-dependent phosphorylation of >200 proteins in skeletal muscle, including mTOR and PDK pathways linked to nutrient uptake .
Heart Failure:
| Intervention | Effect on Cardiac Function | Mechanism |
|---|---|---|
| Chronic UCN2 infusion | Reduced ejection fraction | cAMP/EPAC/CaMKII pathway activation |
| CRHR2 antagonist | Improved cardiac output | Suppression of CREB/MEF2 gene networks |
CRHR2 modulates hypothalamic feeding circuits, with UCN2 suppressing Agrp (orexigenic) and enhancing Pomc (anorexigenic) gene expression .
Knockout models exhibit anxiety-like behaviors and stress hypersensitivity, suggesting CNS-specific regulatory roles .
Heart Failure: CRHR2 antagonists show promise in preclinical models by blocking maladaptive cAMP signaling .
Metabolic Disorders: Receptor desensitization strategies could mitigate insulin resistance in obesity .
Cancer: CRHR2 overexpression in colon cancer correlates with enhanced cell adhesion and metastasis .
siRNA/shRNA: Commercially available constructs (e.g., MISSION esiRNA) for gene silencing in murine and human models .
Antibodies: Validated tools for Western blot (e.g., SAB4500466) and immunohistochemistry (e.g., HPA046683) .
Recombinant Proteins: Expressed in systems like HEK293 cells for ligand-binding assays and structural studies .